Clinical Trial Update: Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice

View source ↗

Summary

A completed clinical trial evaluated how adalimumab (Humira) therapy influences health care resource use and sick leave in patients with ankylosing spondylitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Ankylosing Spondylitis | Status: COMPLETED | Results posted: 2017-03-06